IL6 and pulmonary arterial hypertension: Among the transcriptional profiles evaluated in the PAH subnetwork, only the IL-6 upregulation significantly distinguished IPAH vs. Associated-PAH (Wilcoxon rank sum test, p ≤ 0.05) (Fig. 5) suggesting a potential phenotype-specific biomarker or drug target.